Contrasting Vaccinex (NASDAQ:VCNX) & Capstone (OTCMKTS:CAPS)

Risk and Volatility

Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Capstone has a beta of -0.96, meaning that its share price is 196% less volatile than the S&P 500.

Profitability

This table compares Vaccinex and Capstone’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Capstone	N/A	N/A	N/A

Earnings and Valuation

This table compares Vaccinex and Capstone”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388,000.00	4.69	-$20.25 million	($48.27)	-0.01
Capstone	$44.72 million	0.16	-$7.89 million	($0.95)	-0.91

Capstone has higher revenue and earnings than Vaccinex. Capstone is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 2.5% of Capstone shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by insiders. Comparatively, 59.1% of Capstone shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Capstone beats Vaccinex on 5 of the 9 factors compared between the two stocks.

About Vaccinex

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

About Capstone

Capstone Holding Corp., through its subsidiaries, engages in the distribution of masonry stone products in the United States. Its masonry stone products include manufactured and natural stone cladding products, natural stone landscape products and related goods for residential and commercial construction. The company was formerly known as Capstone Therapeutics Corp. and changed its name to Capstone Holding Corp. in February 2022. Capstone Holding Corp. was incorporated in 1987 and is headquartered in Tempe, Arizona. Capstone Holding Corp. operates as a subsidiary of BP Peptides, LLC.